Adjuvant therapy for women with high-risk endometrial carcinoma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

1. Development and validation of a nomogram for predicting recurrence-free survival in endometrial cancer: a multicenter study.Scientific reports · 2023
   Article
2. The Role of miRNAs in the Development, Proliferation, and Progression of Endometrial Cancer.International journal of molecular sciences · 2023
   Review
3. An integrated approach of network pharmacology, molecular docking, and experimental verification uncovers kaempferol as the effective modulator of HSD17B1 for treatment of endometrial cancer.Journal of translational medicine · 2023
   Article
4. Construction of Endometrial Carcinoma ceRNA Network and Screening of Key Genes Based on TCGA Database.Computational and mathematical methods in medicine · 2022
   Article
5. Systematic Analysis of the Clinical Relevance of Cell Division Cycle Associated Family in Endometrial Carcinoma.Journal of Cancer · 2020
   Article
6. Muscle radiodensity loss during cancer therapy is predictive for poor survival in advanced endometrial cancer.Journal of cachexia, sarcopenia and muscle · 2019
   Article
7. Superparamagnetic iron oxide nanoparticle-mediated expression ofInternational journal of nanomedicine · 2019
   Article

Corrections and comments

• Comment on
  Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.2018

Authors and funding

2 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as